- $56.13bn
- $75.31bn
- $28.43bn
Annual income statement for Medline, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 21,448 | 23,231 | 25,507 | 28,432 |
| Cost of Revenue | ||||
| Gross Profit | 5,217 | 5,885 | 6,976 | 7,518 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 20,587 | 21,981 | 23,361 | 26,220 |
| Operating Profit | 861 | 1,250 | 2,146 | 2,212 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 10 | 264 | 1,246 | 1,248 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -25 | 234 | 1,200 | 1,157 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -25 | 234 | 1,200 | 1,159 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -25 | 234 | 1,200 | 1,159 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.126 | 0.417 | 1.1 | 1.06 |